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The central dilemma in chemotherapy is to eliminate 
the rapidly proliferating cancer cells, while leaving the 
“normal” cells alone as much as possible. Limiting the 
detrimental side effects of mitotic inhibitors on normal 
cells could significantly enhance successful chemotherapy 
[1]. Mitotic inhibitors often kill normal proliferating 
(cycling) cells such as bone marrow cells, hair follicles, 
mucosal and epithelial cells [1-3]. These side effects 
can be severe in some cases and limit the benefits of 
chemotherapy as well as suppress the desirability of 
this type of cancer therapy by certain patients. A central 
question remains how we can improve on chemotherapy 
but reduce its detrimental side effects.
Approximately 50% of human cancers have 
mutations which eliminate the functions of p53. However, 
the normal cells in these cancer patients possess wild-type 
(WT) p53. p53 is often activated by chemotherapeutic 
drugs [1,4,5]. The exciting studies by Apontes et al, 
published in Oncotarget [1], convincingly demonstrate 
that treatment of cells containing WT p53 but not cells 
containing mutant p53 with the MDM-2 inhibitor Nutlin-
3a [6] would protect p53 WT cells put not p53 mutant 
cells from the effects of mitotic inhibitors such as 
paclitaxel and nocodazole. p53 is normally not a stable 
protein due to its ubiquitination by the MDM2 ubiquitin 
ligase. Nutlin-3a acts by inhibiting MDM2 which results 
in p53 stabilization. In essence, these important results 
stem from the basic biological fact that mitotic inhibitors 
cannot cause mitotic arrest in cells that do not enter 
mitosis. Thus in normal cells, a transient arrest in either 
G1 or G2 stimulated by Nutlin-3a treatment, will protect 
them from the catastrophic mitotic arrest induced by 
mitotic inhibitors such as paclitaxel or nocodazole.
Importantly the clinically-approved and readily-
used mTOR inhibitor rapamycin potentiated the protective 
effects of Nutlin-3a in cells with WT p53. Moreover, 
the anti-diabetic drug metformin would interact with 
rapamycin in low glucose cell culture conditions to 
protect cells with WT-p53 but not cells with mutant 
p53. Metformin also inhibits the effects of mTOR and 
reduces glucose and insulin levels [7, 8]. Previous studies 
have indicated that many cancers are mTOR dependent 
[9]. Indeed, mTOR hyperactivation may contribute to 
cancer growth, obesity, diabetes as well as premature 
aging. Many cancers are sensitive to mTOR inhibitors 
[9-11]. In addition, these same mTOR inhibitors may 
suppress premature aging and some are employed to 
treat diabetes and prevent/suppress obesity (metformin). 
Why are these observations presented by Apontes et 
al so important? These results indicate that it may be 
possible to increase the effectiveness of chemotherapy 
by pre-treatment of cancer patients with drugs such as 
Nutlin-3a or combinations of rapamycin and metformin 
to preserve the potential of the normal cells to recover 
after chemotherapeutic drug treatment. That is the normal 
cells will undergo G1 or G2 arrest and not be sensitive 
to the effects of chemotherapeutic drugs (See Figure 1). 
In contrast, cells with mutant p53 will not undergo G1 
or G2 arrest and they will be sensitive to the effects of 
the chemotherapeutic drugs. The authors have proposed 
potential clinical trials to test these important hypotheses.
There are two critical keys to these important 
observations, cancer cells have two potential Achilles 
heels, they are often mutant at p53 and they also require 
high concentrations of glucose to proliferate (Warburg 
effect) via activation of glycolysis followed by lactic acid 
fermentation. Apontes et al exploited the p53 mutation 
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effect by determining the ability of the MDM-2 inhibitor 
Nutlin-3A to protect three different human cell lines 
with WT p53 cells: WI-38t (fibroblast immortalized with 
telomerase), retinal pigment epithelial (RPE) ARPE-19, 
and normal kidney epithelial (NKE) by pretreatment from 
the cytotoxic effects of paclitaxel and nocodazole. Nutlin-
3a causes G1 and/or G2 arrest in cells with WT p53, but 
not in cells with mutant p53 (MDA-MB-231, metastatic 
breast cancer cell line with mutant p53). Thus the cancer 
cells with mutant p53 were sensitive to the effects of 
paclitaxel and nocodazole and underwent lethal mitotic 
arrest even after the removal of the mitotic inhibitors 
and did not regrow when the drugs were removed. In 
contrast, cells with WT p53 did not undergo lethal mitotic 
arrest and recovered and formed colonies. Likewise a 
combination of rapamycin and metformin induced G1 
and G2 arrest in normal cells and protected them from the 
mitotic inhibitors (See Figure 2). These results were also 
observed in low glucose conditions which are toxic for 
the cancer cells. Other studies by this same research group 
have demonstrated the importance of the p53 and mTOR 
pathways in regulating senescence and quiescence [12].
While DNA damaging drugs will induce p53 in 
cells with WT p53, which does to an extent provide some 
protection to the cells, the effects of DNA damaging 
drugs are not always reversible. Thus more effective and 
reversible inducers of p53 have been desired. The small 
molecule inhibitor Nutlin-3a is an effective inducer of p53 
in cells with WT p53 which is more reversible [6,12].
The mTOR pathway is critical in nutrient sensing 
[9-11]. It can be regulated by the drugs rapamycin or 
metformin which act at different points in the pathway. 
Rapamycin targets the key complex mTORC1 which is 
very important in the regulation of translation of mRNAs 
critical in cell growth and survival. Rapamycin is used to 
treat organ transplant patients and is also being evaluated 
as an anti-cancer and anti-aging drug. Rapamycin would 
further potentiate the protective effects of Nutlin-3a 
on cells with WT-p53. Furthermore the combination of 
rapamycin and metformin would further increase the 
Figure 1: Exploiting the p53 Gene Status to Induce Mitotic Catastrophe in p53 Mutant Cells but not in Normal Cells. On 
the left hand side of the figure labeled A, cells with WT p53 undergo cell cycle arrest upon treatment with Nutlin-3a. However if they are then 
treated with chemotherapeutic drugs they do not under go mitotic catastrophe. If the chemotherapeutic drug is removed effectively, the normal 
cells will recover, resume cell cycle progression and grow. On the right hand side of the figure labeled B, in p53 mutant cells, the cells do not 
undergo cell cycle arrest upon treatment with Nutlin-3a. Then upon treatment with chemotherapeutic drugs, the cycling cells undergo mitotic 
catastrophe.
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protective effect. This is most likely due to the different 
molecular effects of rapamycin and metformin on the 
mTOR complex. Rapamycin blocks mTORC1 activity 
[10, 11], while metformin blocks mTORC1 activity by 
perhaps multiple mechanisms depending upon the cell 
type. In some cases metformin may affect Rag GTPases 
[13] while in other cases metformin may inhibit the master 
metabolic regulator, energy-sensing AMP-dependent 
protein kinase (AMPK) which normally activates TSC-
2 and inhibits Raptor [14]. Metformin and rapamycin 
also protected normal cells in low glucose conditions. 
In contrast, the malignant cells, due to their dependence 
on high concentrations of glucose for rapid growth, were 
very sensitive to the effects of metformin and rapamycin 
in low glucose conditions suggesting that dietary (caloric) 
restrictions may aid in certain cancer therapies. Indeed, it 
has become clear over the past few years that obesity can 
contribute to cancer [7,8] and lowering caloric intake may 
augment cancer therapies [15, 16]. High caloric intake 
increases mTOR activity and can contribute to insulin-
resistance, diabetes, obesity and augment cancer growth 
and premature aging. 
The results presented in the exciting manuscript by 
Apontes et al, provide a medical hypothesis by which 
inducing p53 by pre-treatment with Nutlin-3a in cancer 
patients may synergize with two clinically approved 
drugs which target the mTOR pathway, rapamycin and 
metformin to save the normal cells but kill the malignant 
cells upon chemotherapeutic drug treatment.
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